Hai Zhu

机构：EndoGastric Solutions (United States), Aimmune Therapeutics (United Kingdom) · ORCID：0009-0003-1516-0998

发表论文 46 篇 · 总被引 338 次 · h-index 10

代表论文

• Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China (2025 · The Lancet · 被引 19)
• Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial (2025 · Journal of Clinical Oncology · 被引 8)
• Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC). (2025 · Journal of Clinical Oncology · 被引 8)
• Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations. (2025 · Journal of Clinical Oncology · 被引 8)
• Development and external validation of a model for post-endoscopic retrograde cholangiopancreatography pancreatitis (2025 · iScience · 被引 3)
• Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study (2026 · Journal of Clinical Oncology)